# Oral SAR245408 (XL147) and Oral MSC1936369B in Patients With Locally Advanced or Metastatic Solid Tumors

> **NCT01357330** · PHASE1 · COMPLETED · sponsor: **Sanofi** · enrollment: 18 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** SAR245408 (XL147)
- **DRUG:** MSC1936369B

## Key facts

- **NCT ID:** NCT01357330
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2012-06
- **Final completion:** 2012-06
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2016-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01357330

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01357330, "Oral SAR245408 (XL147) and Oral MSC1936369B in Patients With Locally Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01357330. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*